Gunnar Tufveson

TL;DR: MMF significantly reduced the rate of biopsy-proven rejection or other treatment failure during the first 6 months after transplantation and was well tolerated, although the 3 g dose was somewhat less well tolerated.

TL;DR: It is concluded that Scandinavian renal transplant recipients are at high risk of dying of HID, and future advances in long-term renal graft survival will depend largely on the success of preventing myocardial infarction and death in this patient population.

TL;DR: Although the incidence of first acute rejection was similar in CD and LD patients, it was successfully reversed by antirejection treatment in a higher percentage in LD patients and the estimated graft half-life was shorter in patients who had acute rejection episodes than those who did not.

TL;DR: Assessment of two independently performed open‐label, phase 1–2 trials that assessed the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA‐incompatible donor concluded that IdeS reduced or eliminated donor‐specific antibodies and permitted HLA- incompatible transplantation in 24 of 25 patients.

TL;DR: This novel pretreatment procedure prevents intraportal thrombosis and efficiently inhibits the IBMIR without increasing the bleeding risk and, unlike other pretreatment procedures, without inducing acute or chronic toxicity in the islets.